Figure 1
No effect of KIR and HLA genetics on DFS in T cell–replete HLA-matched sibling SCT for AML and MDS. Kaplan-Meier plots with P values obtained from log-rank tests for difference. (A) Effect of missing KIR ligand on DFS. Number (n) of patients: matched (n = 38), mismatched (n = 67). (B) Effect of missing KIR ligand on DFS. Number (n) of patients: matched (n = 38), missing HLA-C1 (n = 14), missing HLA-C2 (n = 17), missing HLA-Bw4 (n = 9), and missing HLA-C1, HLA-C2, and HLA-Bw4, (n = 27).

No effect of KIR and HLA genetics on DFS in T cell–replete HLA-matched sibling SCT for AML and MDS. Kaplan-Meier plots with P values obtained from log-rank tests for difference. (A) Effect of missing KIR ligand on DFS. Number (n) of patients: matched (n = 38), mismatched (n = 67). (B) Effect of missing KIR ligand on DFS. Number (n) of patients: matched (n = 38), missing HLA-C1 (n = 14), missing HLA-C2 (n = 17), missing HLA-Bw4 (n = 9), and missing HLA-C1, HLA-C2, and HLA-Bw4, (n = 27).

Close Modal

or Create an Account

Close Modal
Close Modal